Evaluation of PDE4 inhibition for COPD

Targeting type 4 phosphodiesterase (PDE4) for treatment of COPD has multilevel benefits to patients by reducing inflammation, relieving bronchoconstriction, and improving pulmonary circulation. The isoenzyme-specific narrow spectrum PDE4 inhibitors such as cilomilast and roflumilast may have limited...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Desuo, Cui, Xiangli
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2006
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707810/
https://www.ncbi.nlm.nih.gov/pubmed/18044094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707810/
https://www.ncbi.nlm.nih.gov/pubmed/18044094

Ejemplares similares